**In vitro Modeling of Embryonal Tumors**

**Lars Custers**<sup>1,2†</sup>, **Irene Paassen**<sup>1,2†</sup> and **Jarno Drost**<sup>1,2*</sup>

<sup>1</sup> Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, <sup>2</sup> Oncode Institute, Utrecht, Netherlands

A subset of pediatric tumors affects very young children and are thought to arise during fetal life. A common theme is that these embryonal tumors hijack developmental programs, causing a block in differentiation and, as a consequence, unrestricted proliferation. Embryonal tumors, therefore typically maintain an embryonic gene signature not found in their differentiated progeny. Still, the processes underpinning malignant transformation remain largely unknown, which is hampering therapeutic innovation. To gain more insight into these processes, *in vitro* and *in vivo* research models are indispensable. However, embryonic development is an extremely dynamic process with continuously changing cellular identities, making it challenging to define cells-of-origin. This is crucial for the development of representative models, as targeting the wrong cell or targeting a cell within an incorrect developmental time window can result in completely different phenotypes. Recent innovations in *in vitro* cell models may provide more versatile platforms to study embryonal tumors in a scalable manner. In this review, we outline different *in vitro* models that can be explored to study embryonal tumorigenesis and for therapy development.

**Keywords:** pediatric cancer, embryonal tumors, *in vitro* models, organoids, therapy

**INTRODUCTION**

Cancer is the leading disease-related cause of death in children (Siegel et al., 2016; Cunningham et al., 2018). A significant subset of pediatric tumors occurs in early childhood, suggestive of an origin in prenatal life (Marshall et al., 2014). These so-called embryonal tumors are thought to develop as a consequence of aberrant development. However, for many embryonal tumors the processes driving tumorigenesis remain unknown. Whereas, adult cancers develop by a progressive accumulation of mutations over many years (Stratton et al., 2009), embryonal tumors are typically characterized by a relatively low mutational burden and only a few genetic events to drive tumorigenesis (Vogelstein et al., 2013; Gröbner et al., 2018; Rahal et al., 2018; Kattner et al., 2019). The few genetic alterations that do occur likely cause fetal cells to maintain a progenitor-like state and prohibit differentiation. This maturation block has been suggested to prime cells for malignant transformation (Chen et al., 2015; Puisieux et al., 2018; Rahal et al., 2018; Jessa et al., 2019). To better understand the processes underpinning embryonal...
tumorigenesis, a direct comparison between normal and tumor development is key. Gene expression profiling of fetal tissues with single cell resolution has provided more insights into the developmental trajectories driving embryogenesis. Comparison of such profiles with tumor gene expression signatures have defined the cellular identity of several embryonal tumors, possibly pointing to their cellular origin (Boeva et al., 2017; Young et al., 2018, 2020; Hovestadt et al., 2017; Jessa et al., 2017; Vladoiu et al., 2019). Yet, in many cases these studies are merely correlative and lack subsequent functional validation. To do so, representative \textit{in vitro} and \textit{in vivo} preclinical models are crucial.

Genetically engineered mouse models (GEMMs) have been the golden standard for finding the cellular origin of cancers, by introducing tumor driver events in putative tumor-initiating cells (Vissadler, 2011; Marshall et al., 2014). Although GEMMs have provided important insights into tumorigenesis, several drawbacks limit their potential as a representative model of embryonal tumors. Embryonic development is an extremely dynamic process with continuously changing cellular identities, which makes it very challenging to target the right cell at the right time. For instance, homozygous loss of the Wilms tumor driver gene \textit{Wt1} was shown to be embryonically lethal in mice (Kreidberg et al., 1993), whereas a specific \textit{Wt1} ablation at E11.5 in a small fraction of nephron progenitor cells resulted in Wilms tumor formation (Hu et al., 2011; Berry et al., 2015; Huang et al., 2016). Moreover, GEMM generation is time consuming and mouse development does not fully recapitulate human embryogenesis (Navin et al., 2010, 2011; Blakeley et al., 2015; Theunissen and Jaenisch, 2017). The development of new \textit{in vitro} cell models increasingly recapitulating the complexity of organogenesis will open new avenues for the development of novel, relevant embryonal tumor models. In this review, we discuss the currently available \textit{in vitro} models to study embryonal tumorigenesis as well as the discovery of new therapeutic strategies.

**CELL LINES OF FETAL ORIGIN**

A broad range of cell lines has been established over the last decades. Cell lines are easy to maintain and typically do not consume many resources, which allows for fast and parallel modeling of multiple tumor driver events. This is particularly useful to interrogate the complex genetics underlying heterogeneous tumor phenotypes. One such tumor is neuroblastoma, which is characterized by a variety of driver events, including \textit{MYCN} amplification and \textit{ALK} mutations (Johnsen et al., 2019). To study neuroblastoma initiation, models of its embryonic origin, neural crest (Johnsen et al., 2019), are required. \textit{In vitro} murine neural crest models can be generated by extraction of neural tubes from mouse embryos, which are subsequently placed in a culture dish to initiate the migration of neural crest cells onto the plate (Maurer et al., 2007; Olsen et al., 2017). The neural crest cells lose their multipotency over time \textit{in vitro} (6–10 cell divisions) (Stemple and Anderson, 1992) and are, therefore only suitable for short-term experiments. However, multipotency can be maintained by exogenous c-Myc expression. Accordingly, Maurer et al. (2007) generated the JoMa1 neural crest cell line, which was established from mouse embryos carrying the inducible c-MycER transgene, enabling tamoxifen-inducible c-Myc expression and maintenance of multipotency. In both the JoMa1 cell line, Schulte et al. (2013) and non-genetically modified neural crest cells (Olsen et al., 2017), overexpression of MycN was proven sufficient to generate neuroblastoma upon transplantation in immune-deficient mice. Other murine neural crest-derived neuroblastoma models accommodate oncogenic variants of \textit{Alk} or \textit{Phox2b}, which was shown to impair neural crest development and inhibit sympathoadrenal differentiation processes (Reiff et al., 2010; Schulte et al., 2013; Montavon et al., 2014). However, murine neural crest development has been shown to be different from human in many aspects (O’Rahilly and Müller, 2007; Betters et al., 2010). Cohen et al. (2020), therefore developed a mouse-human chimera to study neuroblastoma formation in a human setting. Human iPSC-derived neural crest cells were injected \textit{in utero} into gastrulating mouse embryos to form a human neural crest lineage in mice. For neuroblastoma modeling, the neural crest cells were subsequently genetically engineered with inducible expression constructs of \textit{MYCN} and an oncogenic variant of \textit{ALK}. Upon induction, mice developed tumors characteristic of patient neuroblastoma, and tumor transcriptomes resembled neuroblastoma patients more closely than GEMMs. Interestingly, injections subcutaneously lead to tumor formation but without expression of neuroblastoma markers (Cohen et al., 2020). These findings suggest that human neural crest cells serve as a more representative model than mouse, but only when generated in the appropriate developmental context and orthotopic environment.

Another embryonal tumor entity where differences between human and mouse models of tumorigenesis were observed is retinoblastoma. The common driver event of retinoblastoma is loss of \textit{Rb1} during retinal development (Dimaras et al., 2015). Retinoblastoma modeling using GEMMs has proven challenging, as engineering of \textit{Rb1}-deficient mice resulted in embryonic lethality (Lee et al., 1992; Wikenheiser-Brokamp, 2006) and retina-specific depletion of \textit{Rb1} was required. However, in contrast to human, mouse retinal cells were proven insensitive to \textit{Rb1} depletion and required additional knockouts of tumor suppressors \textit{p107} or \textit{p130} for retinoblastoma development (Robanus-Maandag et al., 1998; Dannenberg et al., 2004; MacPherson et al., 2004). To generate human models of retinal development, Xu et al. (2014) isolated human fetal retinal cells post-fertilization retaining all retinal precursor cell types (RPCs) at distinct maturation states. Depletion of \textit{Rb1} within the different RPCs indicated post-mitotic cone-precurors to be most prone to develop into retinoblastoma, based on its ability to form tumors with expression of retinoblastoma markers upon xenografting in mice (Xu et al., 2014). Furthermore, \textit{Rb1} loss in matured retinal cells did not induce retinoblastoma, validating that tumor initiation is restricted to a specific cell within retinal development.

Overall, \textit{in vitro} modeling of retinoblastoma and neuroblastoma in human and mouse fetal cell cultures uncovered that fundamental differences between mice and human development can impede representative modeling of embryonal tumors.
**PLURIPOTENT STEM CELL-DERIVED CELL LINES**

Classical cell lines are typically composed of a single type of progenitor-like cell representing a specific germ layer (i.e., endoderm, ectoderm, mesoderm, neural crest). Culture models still capable of generating the different germ layers give the opportunity to model embryonal tumors of which it is not yet clear from which lineage they arise, or which seem to arise across the boundaries of the different germ layers. Current in vitro models capable of recapitulating these different developmental trajectories include pluripotent stem cells (PSCs) such as embryonic stem cells (ESCs) and induced PSCs (iPSCs), which can self-renew and be subjected to differentiation protocols that enforce all germ layers (Liu G. et al., 2020). PSCs can be stably maintained in culture and are permissive for genetic manipulation (Liu G. et al., 2020). With the development of effective differentiation protocols, PSCs can mirror embryonic development and therefore serve as a valuable model to study tumorigenesis. iPSCs are generated through the forced dedifferentiation of somatic cells, which thereby regain pluripotency. The molecular mechanisms that underly this reprogramming show significant similarities with the processes driving a subset of the embryonal germ cell tumors (GCTs) (Oosterhuis and Looijenga, 2019), including yolk sac tumors, embryonal carcinomas, and teratomas. GCTs encompass a diverse group of cancer entities that arise from cells of the early embryo or germ line (Oosterhuis and Looijenga, 2019). Interestingly, somatic mutations play a minor role as drivers of GCT development. Tumors are thought to arise by epigenetic deregulation of the cell-of-origin or aberrant stem cell niche factors (Oosterhuis and Looijenga, 2019). The developmental potency of the cell-of-origin can be reprogrammed through increased expression of well-known pluripotency factors, such as NANOG and OCT4 (De Jong and Looijenga, 2006; Thomas et al., 2011). Xenograft studies have shown that iPSCs and ESCs are intrinsically tumorigenic (Ben-David and Benvenisty, 2011). Upon xenografting, iPSCs develop into a benign GCT referred to as teratoma or in some cases more malignant GCTs, dependent on the reprogramming method applied (Lee et al., 2013). These findings indicate that maintaining an early embryonic cellular context is, by itself, sufficient for tumor initiation. Although PSC tumorigenicity is a limitation for its potential application in regenerative medicine, iPSCs and ESCs can on the other hand serve as in vitro models of GCTs.

A major class of genes mutated in childhood as well as adult cancers are subunits of the SWI/SNF chromatin remodeling complex (Wilson and Roberts, 2011; Shain and Pollack, 2013). The role of this complex in embryonal tumors is clearly exemplified in malignant rhabdoid tumors (MRT), which are characterized by the complete loss of SWI/SNF subunit SMARCB1 (95% of cases) or SMARCA4 (5% of cases) (Lee et al., 2012; Hasselblatt et al., 2014). To study MRT initiation, SMARCB1 was knocked down in hESCs using RNA interference (Langer et al., 2019). The differentiation capacity of hESCs was subsequently assessed, demonstrating that SMARCB1 inhibition specifically repressed neural induction, whereas mesodermal and endodermal lineage induction was not affected (Langer et al., 2019). In culture conditions inducing neural differentiation, SMARCB1 was shown to be essential for increased chromatin accessibility at neural differentiation genes and silencing of pluripotency-related super-enhancers (Wang et al., 2017; Langer et al., 2019). Furthermore, SMARCB1-null iPSCs that were transplanted into mice were able to generate MRT (Terada et al., 2019). Interestingly, iPSCs that had further progressed to neural progenitor cells (NPCs) generated tumors without rhabdoid features. These results show a lineage-specific role for SMARCB1 in vitro, validating recently developed MRT GEMMs wherein Smarcb1 loss-induced rhabdoid tumor development was demonstrated to be limited to a specific developmental time and lineage (Han et al., 2016; Vitte et al., 2017).

A different layer of epigenetic regulation affected in embryonal tumors is the post-translational modification of histone tails, which enables a rapid switch between active or repressive histone marks to dynamically regulate gene expression during development. Mutations in histones are specifically characterized in a subset of pediatric gliomas. In diffuse intrinsic pontine glioma (DIPG), nearly 80% of cases have a missense mutation in the histone 3.3 gene (H3F3A), causing a substitution of methionine for lysine 27 (H3K27M) (Khong-Quang et al., 2012; Schwartzentuber et al., 2012; Wu et al., 2012). The origin of DIPG was indicated to lie in early neural development (Filbin et al., 2018; Sun et al., 2019), presumably making NPCs derived from ESCs a suitable model for tumor initiation. In line with this, overexpression of the H3K27M mutant in NPCs resulted in increased proliferation (Funato et al., 2014). Interestingly, introduction of the mutation was ineffective in uninduced ESCs or mature astrocytes. For a majority of DIPG cases, H3K27M mutations are typically co-occurring with amplification of PDGFRα and loss of TP53 (Khong-Quang et al., 2012). Combined introduction of these three genetic events in NPCs induced more extensive neoplastic features, generating DIPG when transplanted in mice (Funato et al., 2014). This combination of mutations prohibited early NPCs to differentiate to astrocytes (Funato et al., 2014), explaining the observed maturation block in DIPG.

MRT and DIPG modeling approaches using ESCs and iPSCs have demonstrated that a specific cellular context is required for malignant transformation, meaning that tumorigenesis is restricted to a specific developmental time and fetal cell type.

**PLURIPOTENT STEM CELL-DERIVED ORGANOID**

Recent innovations in three-dimensional (3D) culture technology, such as organoids, has opened new opportunities for generating additional representative models of embryonal tumors. Organoids can be derived from adult (ASC) or pluripotent stem cells. They typically capture the cellular and genetic heterogeneity of native tissue and recapitulate cellular hierarchy and dynamics to a large extent, which is most...
likely a consequence of their 3D architecture (Clevers, 2016). Therefore, 3D organoid cultures seem to better recapitulate organ morphogenesis (Clevers, 2016).

Following that rationale, 3D retinal organoids were established from hESCs or iPSCs, allowing for more comprehensive studies of retinoblastoma initiation in human cells (Zhong et al., 2014; Kuwahara et al., 2015). Loss of RB1 in retinal organoids showed a dysregulation of retinal maturation processes, impairing differentiation toward photoreceptors, ganglion, and bipolar cells (Zheng et al., 2020). However, the depletion of RB1 was not sufficient for retinoblastoma initiation as the organoids did not fully recapitulate the retinoblastoma cell phenotype. In addition, transplantation of RB1-null organoids into immune-deficient mice did not result in retinoblastoma formation (Zheng et al., 2020). In contrast, Liu H. et al. (2020) utilized an alternative hESC-derived retinal organoid model, in which RB1 depletion did successfully generate tumors upon xenografting and better resembled patient retinoblastoma. These findings illustrate that the finetuning of retinal organoid establishment can affect the outcome of RB1 depletion, possibly due to differences in cellular composition and the presence or absence of the cell-of-origin. These studies further highlight the specific cellular context required for retinoblastoma initiation and point out a possible limitation of PSC-derived models, as they may not be able to generate the full spectrum of cell-types found in vivo.

A frequent source of embryonal tumors is the embryonic brain. Human brain development can be mimicked by differentiation of PSCs to neural progenitor cells. In culture, they can self-organize into cerebral or cerebellar organoids containing different cell types in a polarized structure (Muguruma et al., 2015; Luo et al., 2016). Embryonic cerebellar organoids have been successfully used to model pediatric brain tumors, including medulloblastoma and rhabdoid tumors (Ballabio et al., 2020; Parisian et al., 2020). Organoid cultures can be utilized to introduce tumorigenic mutations in a systematic manner, as shown for cerebral organoids (Bian et al., 2018), demonstrating the potential for high-throughput in vitro tumor modeling. Furthermore, cerebellar organoids can be exploited to decipher tumor subtype-specific processes. Medulloblastoma, among other embryonal tumor entities, is classified into subtypes based on the oncogenic activation of specific signaling pathways (Cavalli et al., 2017). The medulloblastoma subgroup 3 (MYC amplified subgroup) was successfully modeled in cerebellar organoids by combination of MYC and OTX2 or GFI1 overexpression (Ballabio et al., 2020). The genetically modified cerebellar organoids showed increased proliferation and enrichment for progenitor cells, indicative of a differentiation block. Upon transplantation into mice, medulloblastomas developed resembling subgroup 3 tumors based on marker genes and DNA methylation patterns. Other medulloblastoma subtypes, likely arising from distinct neural differentiation trajectories, have not been modeled in vitro up to date (Gibson et al., 2010; Grammel et al., 2012; Hovestadt et al., 2019). To do so, tumor initiation models composed of different neural lineages may be required.

Overall, the development of embryonic organoid cultures has provided relevant models of embryonal tumorigenesis. By approaching in vivo physiology, human organoids may serve as a promising alternative for time- and labor-intensive in vitro studies.

**REVERSE TUMOR MODELING AND DIFFERENTIATION THERAPY**

Relieving the differentiation block underpinning embryonal tumor development could potentially serve as a therapeutic approach (i.e., maturation therapy). To develop such therapies, the differentiation block must first be defined, which can be achieved through reverse tumor modeling by, for instance, reverting the oncogenic driver in cultured tumor cells. Following this principle, inhibition of N-MYC in MYCN-amplified neuroblastoma cell lines induced a differentiation morphology as well as upregulation of neural differentiation genes (Kang et al., 2006; Henriksen et al., 2011; Jiang et al., 2011; Westermak et al., 2011; Hossain et al., 2013). Differentiation phenotypes were also observed upon genetic manipulation of medulloblastoma models (Liu et al., 2017; Cheng et al., 2020; Zagoezowski et al., 2020), and MRT models (Betz et al., 2002; Nakayama et al., 2017; Wang et al., 2017). These studies show that reversal of the genetic driver can transform tumor cells to a more mature cell state, possibly reflecting the matured cell type it would have become, had it not become cancerous. Genetic repair of driver genes is not feasible at present (Dunbar et al., 2018). An alternative strategy is to induce differentiation pharmacologically. For instance, experiments performed in MRT models with SMARCB1 re-expression identified EZH2 and BRD9 as promising therapeutic targets (Erkek et al., 2019; Wang et al., 2019). Moreover, aberrant epigenetic regulation is often causal of the malignant embryonic state of pediatric cancer cells (Lawlor and Thiele, 2012), potentially explaining the sensitivity of different embryonal tumors to drugs targeting epigenetic modifiers (Table 1). Treatment of in vitro pediatric tumor models with differentiation agents can recapitulate the effects achieved by driver reversal. However, a durable effect of differentiation therapy can only be acquired through induction of an irreversible growth arrest. As in vivo studies have shown, single agent treatment may not suffice to induce terminal differentiation and that combination therapy is required to do so (Hahn et al., 2008; Botrugno et al., 2009; Westerlund et al., 2017; Chen et al., 2018). A powerful tool to identify new (combinations of) drugs are high-throughput drug screens performed on in vitro tumor models. Organoids directly derived from patient tumor tissue could provide such models, as they have been shown to closely resemble its parental tissue (Drost and Clevers, 2018). Confirming their potential, an increasing number of reports described that tumor organoids are predictive for patient drug response (Tiriac et al., 2018; Vlachogiannis et al., 2018; Ganesh et al., 2019; Ooft et al., 2019; Yao et al., 2020). Recently, the organoid technology was also successfully applied to several pediatric cancers, including embryonal tumors such as MRT and Wilms tumors (Schutgens et al., 2019; Calandrini et al., 2020). The efficient establishment and cryopreservation of tumor organoid models from primary patient tissue allows for the generation of large patient cohorts.
**TABLE 1 | In vitro embryonic tumor initiation models and differentiation therapies.**

| Tumor         | Origin            | In vitro models                                                                 | Differentiation therapy                                      |
|---------------|-------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------|
| Neuroblastoma | Neural crest cells (NCCs) | MYCN overexpression in mouse primary NCCs (Olsen et al., 2017)                  | Retinoic acid treatment (Lone et al., 2016; Westerlund et al., 2017) |
|               |                    | MYCN/ALK-F1174L overexpression in a mouse NC-cell line (Schulte et al., 2013)  | HDAC inhibitors (Hahn et al., 2006; Frumm et al., 2013)      |
|               |                    | Mouse-human chimeras with MYCN overexpression in iPSC-derived hNCCs (Cohen et al., 2020) | EZH2 inhibitors (Chen et al., 2018)                         |
|               |                    | Engineering human 1p36 deletions in mouse NCCs (Garcia-Lopez et al., 2020)       |                                                             |
| MRT           | Neural crest cells (NCCs) | SMARCB1 knockout in iPSCs (Terada et al., 2019)                                | HDAC inhibitors (Muscat et al., 2016)                        |
|               |                    | SMARCB1 knockdown in ESCs (Langer et al., 2019)                                | EZH2 inhibitors (Knutson et al., 2013)                       |
| Medulloblastoma | Neural progenitor cells | c-MYC overexpression in cerebellar organoids (Ballabio et al., 2020)            | Retinoic acid treatment (Patties et al., 2016)               |
|               |                    | MYCN overexpression in neuroepithelial stem cells (Huang et al., 2019)          | EZH2 inhibitors (Cheng et al., 2020)                         |
| DIPG          | Oligodendrocyte precursor cells | H3K27M mutations in hESC derived NPCs (Funato et al., 2014)                     | SHH inhibitors (Ocasio et al., 2019)                        |
|               |                    | ACVR1 mutations in neurospheres (Hoeman et al., 2019)                           | BET-bromodomain inhibitors (Bandopadhyay et al., 2019)      |
| Retinoblastoma | Cone precursor cells | RB1 depletion in fetal retinal cell cultures (Xu et al., 2014)                  | HDAC inhibitors (Anastas et al., 2019)                       |
|               |                    | RB1 depletion in hESC derived retinal organoids (Liu H. et al., 2020; Zheng et al., 2020) | BET-bromodomain inhibitors (Mohammad et al., 2017)           |

**FIGURE 1 | Overview of embryonal tumor modeling techniques.** Illustration that summarizes the different in vitro approaches used to model embryonal tumors (MRT = malignant rhabdoid tumor; DIPG = diffuse intrinsic pontine glioma; GCT = germ cell tumor). In vitro tumor models are grouped by their source: cell lines of fetal origin, 2D embryonic stem cell (ESC) derived or induced pluripotent stem cell derived (iPSC) cell lines and 3D ESC/iPSC derived organoids. The gene-editing of tumor driver events is indicated (red = loss of function/deletions; green = gain of function/overexpression). Permission to reuse and Copyright: Medical illustrations used in this figure were modified from Servier Medical Art, licensed under a Creative Commons Attribution 3.0 Generic License.
stored in organoid biobanks. This is seemingly of particular interest for rare tumors, such as embryonal tumors, for which research material is scarce. In conclusion, the generation of novel and more representative in vitro embryonal tumor models is key for the improvement of differentiation therapeutics.

**DISCUSSION**

In this review, we have attempted to outline the rapidly developing field of in vitro embryonal tumor models and discussed their added value to embryonal tumor research (Figure 1 and Table 1). Still, each model has its intrinsic limitations. For instance, fetal cells can be extracted and cultured from fetal tissues (Xu et al., 2014), but in many cases they do not represent the continuously changing cellular identities found during embryonic development. Alternatively, iPSCs or ESCs cell lines can be deployed to recapitulate these dynamics. Still, even though the spectrum of differentiation protocols is rapidly expanding, many embryonic cell types found in vivo cannot yet be captured in vitro. Additionally, in vitro cultures of ESCs or iPSCs have been shown to be susceptible to “spontaneous” malignant transformation, which can complicate the interpretation of modeling experiments (Ben-David and Benvenisty, 2011). Furthermore, 2D cultures do not capture 3D tissue architecture (Pampaloni et al., 2007). These limitations have been to some extent improved in 3D organoid cultures, which better capture the cell-cell interactions found during embryonic organogenesis (Clevers, 2016). The development of mouse-human chimeras has highlighted the role of the microenvironment in tumor progression (Cohen et al., 2020) and reveals a promising opportunity to bridge the gap of in vitro and in vivo tumor modeling, as mouse-human chimeras have the advantage of having human cells combined with an in vivo murine microenvironment. A good representation of patient tumor evolution remains challenging in in vitro models. In patients, tumors originate from a single tumor-initiating cell, wherein a genetic driver event induces aberrant signaling pathways that provide a cell with competitive advantages. Continuous selection of such cells (clonal selection) is thought to form the basis of tumor initiation, progression, and heterogeneity (Navin et al., 2010, 2011). In vitro models typically do not reflect the environmental conditions causing clonal selection, as culture conditions are only a simplified version of in vivo signaling complexity. Embryonal tumors maintain a fetal identity, which is no longer present in matured tissues (Orbach et al., 2013; Marshall et al., 2014). The characterization of developmental programs in embryonal tumors can therefore give crucial insights into the processes underpinning malignant growth. Single cell transcriptome profiling of tumors and developing tissues has proven to be a promising tool to reveal such processes, which could potentially serve as therapeutic targets (Filbin et al., 2018; Zhang et al., 2019). Similar methods can also be applied to in vitro models recapitulating embryonal tumorigenesis, as demonstrated for the retinoblastoma organoid model generated by Liu H. et al. (2020), which has the advantage that it allows for a direct comparison of normal and tumor development.

Although many in vitro embryonic cell-derived tumor models have been established over the years, the spectrum is biased toward ectoderm-derived tumors. It seems a matter of time before mesoderm- or endoderm-derived in vitro tumor models (e.g., Wilms tumor and hepatoblastoma) will be developed, as the number of culture systems for fetal tissues is rapidly expanding (Low et al., 2019; Ooms et al., 2020; Hendriks et al., 2021).

We are only just beginning to understand the complexity of embryonal tumor development. Although capturing this complexity in a single in vitro model might not be feasible, further development of representative in vitro cell models recapitulating at least part of it is crucial to gain further insight into the fundamental processes underpinning malignant growth and the development of new therapeutic strategies.

**AUTHOR CONTRIBUTIONS**

LC, IP, and JD wrote the manuscript. JD supervised the work. All authors approved the manuscript for publication.

**FUNDING**

We are grateful for support from the European Research Council (ERC) starting Grant 850571 (JD), the Dutch Cancer Society (KWF)/Alpe d’HuZes Bas Mulder Award to JD (KWF/Alpe d’HuZes, 10218), and the Children Cancer-free Foundation (KiKa #338, LC; base funding, IP).

**REFERENCES**

Anastas, I. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., et al. (2019). Re-programming chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG. Cancer Cell 36, 528–544.e10. doi: 10.1016/j.ccell.2019.09.005

Ballabio, C., Anderle, M., Gianesello, M., Lago, C., Miele, E., Cardano, M., et al. (2020). Modeling medulloblastoma in vivo and with human cerebellar organoids. Nat. Commun. 11:583. doi: 10.1038/s41467-019-139-9

Betz, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S., and Weissman, B. E. (2002). Analysis of early human neural crest development. Dev. Biol. 248, 578–592. doi: 10.1006/dbio.2002.0376

Berg, R. L., Ozdemir, D. D., Aronow, B., Lindstrom, N. O., Dudnakova, T., Thornburn, A., et al. (2015). Deducing the stage of origin of Wilms’ tumours from a developmental series of Wt1-mutant mice. DMM Dis. Models Mech. 8, 903–917. doi: 10.1242/dmm.018523

Betters, E., Liu, Y., Kjaeldgaard, A., Sundstrom, E., and Garcia-Castro, M. I. (2010). Analysis of early human neural crest development. Dev. Biol. 344, 578–592. doi: 10.1016/j.ydbio.2010.05.012

Ben-David, U., and Benvenisty, N. (2011). The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat. Rev. Cancer 11, 268–277. doi: 10.1038/nrc3034

Berry, R. L., Ozdemir, D. D., Aronow, B., Lindstrom, N. O., Dudnakova, T., Thornburn, A., et al. (2015). Deducing the stage of origin of Wilms’ tumours from a developmental series of Wt1-mutant mice. DMM Dis. Models Mech. 8, 903–917. doi: 10.1242/dmm.018523

Betters, E., Liu, Y., Kjaeldgaard, A., Sundstrom, E., and Garcia-Castro, M. I. (2010). Analysis of early human neural crest development. Dev. Biol. 344, 578–592. doi: 10.1016/j.ydbio.2010.05.012

Betzi, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S., and Weissman, B. E. (2002). Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to spontaneous malignant transformation, which can complicate the interpretation of modeling experiments (Ben-David and Benvenisty, 2011). Furthermore, 2D cultures do not capture 3D tissue architecture (Pampaloni et al., 2007). These limitations have been to some extent improved in 3D organoid cultures, which better capture the cell-cell interactions found during embryonic organogenesis (Clevers, 2016). The development of mouse-human chimeras has highlighted the role of the microenvironment in tumor progression (Cohen et al., 2020) and reveals a promising opportunity to bridge the gap of in vitro and in vivo tumor modeling, as mouse-human chimeras have the advantage of having human cells combined with an in vivo murine microenvironment. A good representation of patient tumor evolution remains challenging in in vitro models. In patients, tumors originate from a single tumor-initiating cell, wherein a genetic driver event induces aberrant signaling pathways that provide a cell with competitive advantages. Continuous selection of such cells (clonal selection) is thought to form the basis of tumor initiation, progression, and heterogeneity (Navin et al., 2010, 2011). In vitro models typically do not reflect the environmental conditions causing clonal selection, as culture conditions are only a simplified version of in vivo signaling complexity. Embryonal tumors maintain a fetal identity, which is no longer present in matured tissues (Orbach et al., 2013; Marshall et al., 2014). The characterization of developmental programs in embryonal tumors can therefore give crucial insights into the processes underpinning malignant growth. Single cell transcriptome profiling of tumors and developing tissues has proven to be a promising tool to reveal such processes, which could potentially serve as therapeutic targets (Filbin et al., 2018; Zhang et al., 2019). Similar methods can also be applied to in vitro models recapitulating embryonal tumorigenesis, as demonstrated for the retinoblastoma organoid model generated by Liu H. et al. (2020), which has the advantage that it allows for a direct comparison of normal and tumor development.
Boeva, V., Louis-Brennetot, C., Peltier, A., Durand, S., Pierre-Eugène, C., Raynal, V., et al. (2017). Heterogeneity of neuroblastoma cell identity defined by transcriptional circitities. Nat. Genet. 49, 1408–1413. doi: 10.1038/ng.3921

Borutro, O. A., Santoro, F., and Minucci, S. (2009). Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett. 280, 134–144. doi: 10.1016/j.canlet.2009.02.027

Calandrini, C., Schutgens, F., Oka, R., Margaritis, T., Candelli, T., Mathijsen, L., et al. (2020). An organoid biobank for childhood cancers that captures disease and tissue heterogeneity. Nat. Commun. 11:1310. doi: 10.1038/s41467-020-15155-6

Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., et al. (2018). In vitro Genetics of death in children and adolescents in the United States. N. Eng. J. Med. 379, 2468–2475. doi: 10.1056/nejmsr1804754

Dannenberg, J. H., Schauff, L., Dekker, M., Van Der Valk, M., and Te Riele, H. (2006). Stem cell marker OCT3/4 in tumor development. Cell Stem Cell 31, 346–355. doi: 10.1016/j.stem.2006.09.009

Funato, K., Major, T., Lewis, P. W., Allis, C. D., and Tabar, V. (2014). Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science.aao4673. February 22, 2021 Time: 19:18 # 7
Kattner, P., Strobel, K., Khoshnevis, N., Grunert, M., Bartholomae, S., Pruss, M., et al. (2019). Compare and contrast: pediatric cancer versus adult malignancies. Cancer Metastasis Rev. 38, 673–682. doi: 10.1007/s10555-019-09836-y
Khuan-Quang, D. A., Buczko, P., Rakopoulos, P., Li, X. Y., Fontebasso, A. M., Bouffet, E., et al. (2012). K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124, 439–447. doi: 10.1007/s00401-012-0998-0
Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, S. C., et al. (2017). EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat. Med. 23, 483–492. doi: 10.1038/nm.4293

Montavon, G., Jausiquier, N., Coulon, A., Pechmair, M., Flahaut, M., Bourlouid, K. B., et al. (2014). Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate MUC and initiate tumor formation in murine neural crest progenitor cells. Oncotarget 5, 4452–4466. doi: 10.18632/oncotarget.2036
Miguruma, K., Nishiyama, A., Kawakami, H., Hashimoto, K., and Sasai, Y. (2015). Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep. 10, 537–550. doi: 10.1016/j.celrep.2014.12.051
Muscat, A., Popovski, D., Jayasekara, W. S. N., Rossello, F. J., Ferguson, M., Marini, K. D., et al. (2016). Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors. Clin. Cancer Res. 22, 3560–3570. doi: 10.1158/1078-0432.CCR-15-2260
Nakayama, R. T., Pulice, J. L., Valencia, A. M., McBride, M. J., McKenzie, Z. M., Gillespie, M. A., et al. (2017). SMARCB1 is required for widespread RAG complex-mediated activation of enhancers and bivalent promoters. Nat. Genet. 49, 1613–1623. doi: 10.1038/ng.3958
Navin, N., Kendall, J., Troke, J., Andrews, P., Rodgers, L., Mcclando, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature 472, 90–95. doi: 10.1038/nature09807

Navin, N., Krasnitz, A., Rodgers, L., Cook, K., Meth, J., Kendall, J., et al. (2010). Infiltrating tumor progression from genomic heterogeneity. Genome Res. 20, 68–80. doi: 10.1101/gr.99622.109

Occaso, I., Babcock, B., Malawsky, D., Weir, S. J., Loo, S., Simon, J. M., et al. (2019). scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Nat. Commun. 10:5829. doi: 10.1038/s41467-019-13657-6

Olsen, R. R., Otero, J. H., García-López, J., Wallace, K., Finkelstein, D., Rehg, J. E., et al. (2017). MYCN induces neuroblastoma in primary neural crest cells. Oncogene 36, 5075–5082. doi: 10.1038/onc.2017.128

Osof, S. N., Weeber, D., Dijkstra, K. K., Mclean, C. M., Kaing, S., van Werkhoven, E., et al. (2019). Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Sci. Trans. Med. 11 eaay2574. doi: 10.1126/scitranslmed.aay2574

Ooms, A. H. A. G., Calandrini, C., de Krijger, R. R., and Drost, J. (2020). Organoid models of childhood kidney tumours. Nat. Rev. Urol. 17, 311–313. doi: 10.1038/s41585-020-0315-y

Oosterhuis, J. W., and Looijenga, L. H. J. (2019). Human germ cell tumours from a developmental perspective. Nat. Rev. Cancer 19, 522–537. doi: 10.1038/s41566-019-0178-9

O’Rahilly, R., and Müller, F. (2007). The development of the neural crest in the human. J. Anatomy 211, 335–351. doi: 10.1111/j.1469-7580.2007.00773.x

Orbach, D., Sarnacki, S., Brisse, H. J., Gauthier-Villars, M., Jarreau, P. H., Tsatsaris, V., et al. (2013). Neonatal cancer. Lancet Oncol. 14, e609–e620. doi: 10.1016/s1470-2045(13)70236-5

Pampaloni, F., Reynaud, E. G., and Steltzer, E. H. K. (2007). The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8, 839–845. doi: 10.1038/nrm2236

Parisian, A. D., Koga, T., Miki, S., Johann, P. D., Kool, M., Crawford, J. R., et al. (2020). SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability. Genes Dev. 34, 1316–1329. doi: 10.1101/gad.33978.120

Patties, I., Kortmann, R. D., Menzel, F., and Glasow, A. (2016). Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs. J. Exp. Clin. Cancer Res. 35:1. doi: 10.1186/s41304-016-0376-1

Puisieux, A., Pommier, R. M., Morel, A. P., and Lavial, F. (2018). Cellular pliancy and the multistep process of tumorigenesis. Cancer Cell 33, 164–172. doi: 10.1016/j.ccell.2018.01.007

Rahal, Z., Abdulhadi, F., Kadara, H., and Saab, R. (2018). Genomics of adult and pediatric solid tumors. Am. J. Cancer Res. 8, 1356–1386.

Reiff, T., Tsarovina, K., Majdazari, A., Schmidt, M., Del Pino, I., and Rohrer, H. (2017). Conditional transgenesis. J. Neurosci. 37, 1277–289. doi: 10.1523/JNEUROSCI.5368-09.2010

Sarver, D. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Ecker, J. R., et al. (2017). EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat. Med. 23, 483–492. doi: 10.1038/nm.4293

Streeter, G. L., and Sargent, A. (2014). Prenatal origins of cancer. Nat. Rev. Cancer 14, 277–289. doi: 10.1038/nrc3679

Streeter, G. L., and Sargent, A. (2014). Prenatal origins of cancer. Nat. Rev. Cancer 14, 277–289. doi: 10.1038/nrc3679
development in pRb-deficient mice. Genes Dev. 12, 1599–1609. doi: 10.1101/gad.12.11.1599
Schulte, J. H., Lindner, S., Bohrer, A., Maurer, J., De Preter, K., Lefever, S., et al. (2013). MYCN and ALKFI174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 32, 1059–1065. doi: 10.1038/onc.2012.106
Schutgens, F., Rookmaaker, M. B., Margaritis, T., Rios, A., Ammerlaan, C., Jansen, J., et al. (2019). Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat. Biotechnol. 37, 303–313. doi: 10.1038/s41587-019-0048-8
Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T. W., Pfaff, E., Jacob, K., et al. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226–231. doi: 10.1038/nature10833
Shain, A. H., and Pollack, J. R. (2013). The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One 8:e55119. doi: 10.1371/journal.pone.0055119
Siegel, R. L., Miller, K. D., and Jemal, A. (2016). Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30. doi: 10.3322/caac.21332
Stemple, D. L., and Anderson, D. J. (1992). Isolation of a stem cell for neurons and glia from the mammalian neural crest. Cell 71, 973–985. doi: 10.1016/0092-8674(92)90393-Q
Stratton, M. R., Campbell, P. J., and Futreal, P. A. (2009). The cancer genome. Nature 458, 719–724. doi: 10.1038/nature07943
Sun, Y., Xu, C., Pan, C., Chen, X., Geng, Y., Wu, Y., et al. (2019). Diffuse intrinsic pontine gliomas exhibit cell biological and molecular signatures of fetal hindbrain-derived neural progenitor cells. Neurosci. Bull. 35, 216–224. doi: 10.1007/s12264-018-00329-6
Terada, Y., Jo, N., Arakawa, Y., Sakakura, M., Yamada, Y., Ukai, T., et al. (2019). Human pluripotent stem cell-derived tumor model uncovers the embryonic stem cell signature as a key driver in atypical teratoid/rhabdoid tumor cell. Cell Rep. 26, 2608–2621.e6. doi: 10.1016/j.celrep.2019.02.009
Theunissen, T. W., and Jänicsh, R. (2017). Mechanisms of gene regulation in human embryos and pluripotent stem cells. Development (Cambridge) 144, 4496–4509. doi: 10.1242/dev.157404
Thomas, J., Adegboyega, P., Illoabachie, K., Mooring, J. W., and Lian, T. (2011). Sinonasal teratocarcinosarcoma with yolk sac elements: a neoplasm of somatic human embryos and pluripotent stem cells. Annals Diagn. Pathol. 15, 135–139. doi: 10.1016/j.anndiagpath.2010.01.004
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., et al. (2018). Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discovery 8, 1112–1129. doi: 10.1158/2159-8290.CD-18-0349
Wang, X., Lee, R. S., Alver, B. H., Haswell, J. R., Wang, S., Miezczkowski, J., et al. (2017). SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat. Genet. 49, 289–295. doi: 10.1038/ng.3746
Wang, X., Wang, S., Troisi, E. C., Howard, T. P., Haswell, J. R., Wolf, B. K., et al. (2019). BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. Nat. Commun. 10.1038/s41467-019-08991-7
Westerdal, L., Shi, Y., Tsuchiya, K., Fell, S. M., Li, S., Surova, O., et al. (2017). Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression. Proc. Natl. Acad. Sci. U. S. A. 114, E6137–E6146. doi: 10.1073/pnas.1700655114
Westerman, U. K., Wilhelm, M., Frenzel, A., and Henriksson, M. A. (2011). The MYCN oncopGene and differentiation in neuroblastoma. Sem. Cancer Biol. 21, 256–266. doi: 10.1016/j.semcancer.2011.08.001
Wikenheiser-Brokamp, K. A. (2006). Retinoblastoma family proteins: gains insight through genetic manipulation of mice. Cell. Mol. Life Sci. 63, 767–780. doi: 10.1007/s00018-005-5487-3
Wilson, B. G., and Roberts, C. W. M. (2011). SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481–492. doi: 10.1038/nrc3068
Wu, G., Broniscer, A., McEchron, T. A., Lu, C., Paugh, B. S., Becksfort, J., et al. (2012). Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet. 44, 251–253. doi: 10.1038/ng.1102
Xu, X. L., Singh, H. P., Wang, L., Qi, D. L., Poulos, B. K., Abramson, D. H., et al. (2014). Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 514, 385–388. doi: 10.1038/nature13813
Yao, X., Xu, X., Yang, L., Zhu, J., Wan, J., Shen, L., et al. (2020). Patient-Derived organoids predict chemoradiation responses of locally advanced rectal cancer. Cell Stem Cell 26, 17–26.e6. doi: 10.1016/j.stem.2019.10.010
Young, M. D., Mitchell, T. J., Custers, L., Margaritis, T., Morales, F., Kwakwa, K., et al. (2020). Single cell derived mRNA signals across human kidney tumors. BioRxiv [preprint] doi: 10.1101/2020.03.19.998815
Young, M. D., Mitchell, T. J., Vieira Braga, F. A., Tran, M. G. B., Stewart, B. J., Ferdinand, J. R., et al. (2018). Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Science 361, 594–599. doi: 10.1126/science.aat1699
Zagosewski, J., Shahriary, G. M., Morrison, L. C., Saulnier, O., Stromecki, M., Fresnoza, A., et al. (2020). An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nat. Commun. 11:3627. doi: 10.1038/s41467-020-17357-4
Zheng, C., Chen, A., Li, L., Huang, L. F., Potter, A. S., et al. (2019). Single-Cell transcriptomics in medulloblastoma reveals tumor-initiating progenitors and oncogenic cascades during tumorigenesis and relapse. Cancer Cell 36, 302–318.e7. doi: 10.1016/j.ccell.2019.07.009
Zheng, C., Schneider, J. W., and Hsieh, J. (2020). Role of RB1 in human embryonic stem-cell-derived retinoblastoma tumours. Dev. Biol. 462, 197–207. doi: 10.1016/j.ydbio.2020.03.011
Zhong, X., Gutierrez, C., Xue, T., Hampton, C., Vergara, M. N., Cao, L. H., et al. (2019). Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs. Nat. Commun. 5:4047. doi: 10.1038/s41467-018-02212-2
Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.